Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
Conditions : Grade 2 IDH1-mutant Glioma; Grade 3 IDH1-mutant Glioma; Glioma; IDH1-mutant Glioma; Oligodendroglioma; Oligodendroglioma IDH-1 Mutant and 1/p19q-codeleted; Astrocytoma IDH Mutant Grade…
Read the full article3d agoen
You might also wanna read
Preadmission GLP-1 Receptor Agonist Plus SGLT2 Inhibitor Use and Early Outcomes After Pneumonia Hospitalization in Adults With Type 2 Diabetes
clinicaltrials.gov·just now
Comprehensive study finds no link between mobile phones and brain cancer
theconversation.com·1h agoNew CRISPR Tool Enables Control of Ribosomal RNA to Target Protein-Related Diseases
scitechdaily.com·1h ago

Comments
Sign in to join the conversation.
No comments yet. Be the first.